Nanoparticles for lung cancer pass next test

April 11, 2018, Thomas Jefferson University
Lung CA seen on CXR. Credit: James Heilman, MD/Wikipedia

The most common type of lung cancer, non-small cell lung cancer (NSCLC), continues to be difficult to treat, with five year survival rates of about 36 percent for stage 3A tumors. Jefferson College of Pharmacy researchers are developing a new treatment approach based on nanotechnology that was recently shown to be effective in mouse models of the disease. The research was published in the journal Molecular Pharmaceutics.

The nanoparticles were designed to deliver a molecule that's been shown to stall growth and may make tumors more susceptible to chemotherapy. The molecule, called microRNA 29b, would be ineffective if delivered by injection alone, as it quickly becomes degraded in the bloodstream or picked up and removed by immune cells.

To bypass these limitations, Sunday Shoyele, PhD, Associate Professor in the Department of Pharmaceutical Sciences at Jefferson (Philadelphia University + Thomas Jefferson University) and colleagues, developed a nanoparticle comprised of four parts. First, Dr. Shoyele included part of a human antibody, immunoglobulin G (IgG), to cloak the particle from the immune system. Second, the research team added the MUC1 antigen, which acts like a navigation system guiding the to the MUC1-covered lung tumors. Finally, the therapeutic payload, microRNA-29b, along with the other two components are glued together using a sticky polymer called poloxamer-188.

Dr. Shoyele and colleagues showed that these components formed a spherical nanoparticle capable of properly finding the tumors and shrinking the tumors in mouse models of the disease. "This work extends our previous work demonstrating that these particles were effective in shrinking tumor tissue in a petri dish. Here we show that they are also effective in a more complex living system," said Dr. Shoyele.

Additional tests are needed before the technology is ready for testing in human clinical trials. Dr. Shoyele plans to continue the research with comprehensive toxicity tests and scaling the nanoparticle manufacturing process for clinical trials.

Explore further: Researchers develop novel immunotherapy to target colorectal cancer

More information: Maryna Perepelyuk et al, Evaluation of MUC1-Aptamer Functionalized Hybrid Nanoparticles for Targeted Delivery of miRNA-29b to Nonsmall Cell Lung Cancer, Molecular Pharmaceutics (2018). DOI: 10.1021/acs.molpharmaceut.7b00900

Related Stories

Nano packages for anti-cancer drug delivery

March 18, 2015

Cancer stem cells are resistant to chemotherapy and consequently tend to remain in the body even after a course of treatment has finished, where they can often trigger cancer recurrence or metastasis. A new study by researchers ...

Recommended for you

Water matters to metal nanoparticles

August 14, 2018

When you purchase anything from makeup to paint to sunscreen, chances are it contains engineered nanoparticles. These nanoscale materials have properties that are revolutionizing products—from medicine to agriculture to ...

Controlling nickelate nano-switches with light

August 14, 2018

Dr. Giordano Mattoni, quantum researcher at TU Delft, and his collaborators have shown that the nano-electronic phase transition in a class of materials known as nickelates can be controlled by laser light. Their findings, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.